Further improvement after 24-month treatment with teduglutide in a patient with active Crohn’s disease and short bowel syndrome

Kaynakça (1)

1. Tee CT, Wallis K, Gabe SM. Emerging treatment options for short bowel syndrome: potential role of teduglutide. Clin Exp Gastroenter-ol 2011; 4: 189-96. [CrossRef] 6. Sinh P, Shen B. Endoscopic evaluation of surgically altered bow-el in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015; 21: 1459-71. [CrossRef] 5. Vilela EG, Torres HO, Martins FP, Ferrari Mde L, Andrade MM, Cunha AS. Evaluation of inflammatory activity in Crohn’s disease and ulcer-ative colitis. World J Gastroenterol 2012; 18: 872-81. [CrossRef] 4. Borghini R, Caronna R, Picarelli A, Corazziari ES. Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn’s disease. Turk J Gastroenter-ol 2017; 28: 73-4. [CrossRef] 3. Pape UF, Maasberg S, Pascher A. Pharmacological strategies to enhance adaptation in intestinal failure. Curr Opin Organ Transplant 2016; 21: 147-52. [CrossRef] 2. Iyer KR, Kunecki M, Boullata JI, et al. Independence from paren-teral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome. JPEN J Parenter Enteral Nutr 2017; 41: 946-51 1. Billiauws L, Bataille J, Boehm V, Corcos O, Joly F. Teduglutide for treatment of adult patients with short bowel syndrome. Expert Opin Biol Ther 2017; 17: 623-32. [CrossRef]